ICON plc Goldman Sachs Twenty Sixth Annual Global Healthcare Conference 14 th June 2005 ICON plc Goldman Sachs Twenty Sixth Annual Global Healthcare Conference 14 th June

Overview Certain statements contained herein including, without limitation, statements containing the words “believes,” “anticipates,” “intends,” “expects” and words of similar import, constitute forward-looking statements concerning the Company's operations, performance, financial condition and prospects. Because such statements involve known and unknown risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward Looking Statements

Global Full Service Drug Development >$300m in Revenues 37 Offices in 23 Countries Pre-clinicalPhase IPhase IIPhase IIILaunchPhase IV 6% Strategic Drug Development and Regulatory Consulting (US & EU) 5% Phase I 8% Central lab (Global) 16% Data Management & Statistical Consulting (Global) 57% Trial Management & Monitoring (Global) 2.5% Contract Staffing (US) 2.5% Central Imaging Lab (US & EU) 3% IVRS (Global)

Use “Full Service” to Leverage Client Relationships and Capture more of the Spend Strategic Product Development / Consulting 6% Strategic Product Development / Consulting 6% Clinical Trial Management Phase II – IV 57% Clinical Trial Management Phase II – IV 57% Phase I 5% Phase I 5% Central Laboratory 8% Central Laboratory 8% IVRS 2.5% IVRS 2.5% Contract Staff 3% Contract Staff 3% Central Imaging Lab 2.5% Central Imaging Lab 2.5% Data Management & Biostatistics 16% Data Management & Biostatistics 16%

Strong Market Environment R&D Spending Growth Improving Pipelines ~ more outsourcing Biotech / Specialty Companies Regulatory Environment Preferred Providers

Phase II – IV RFP Volume / Value Trends Q4 FY04 v Q4 FY05www.iconclinical.com RFP Value GrowthRFP Volume Growth Geography = locus of work, not of client

Current Issues / Strategic Development

ICON Has Traditionally Experienced Low Cancellation Rates but in August 04 …… Cancellations as % of Opening Backlog $46m cancellations inc. 2 major projects

Current Tactical Issues Recovery from Exceptional Cancellation Quarter to Restore Growth Net Wins $120m in Nov ‘04 Qtr and $106m in Feb ’05 Qtr Solid net wins again expected in May 05 quarter Current RFP flow excellent Capitalise on Lab Investments and Sales Success to Eliminate Losses Continue Sales Success Add more major clients Continue to develop technological base Phase I business now back in profit post EU Clinical Trials Directive

ICON LABS Net New Business Wins Net Business Wins Book to Bill Ratio Average Book-to-Bill 1.4

Current Strategic Initiatives Investing in Operations in Japan – first significant project won in May Creation of Data Management Operation in India – now 40 people and growing Partnership with Medidata Solutions in EDC – gaining traction Developing specialised Phase IV Division New IT in 2005 to enhance quality, efficiency and customer service New Trial Management and Project Collaboration Systems New Document Management System New eLearning System

Investment Highlights Global Major Late Stage CRO Outstanding track record of organic growth Strong fundamentals underpinning business At significant discount to peers as market awaits clear signs of recovery from cancellations and in performance of Lab Strong cash position and balance sheet